Special Issue "Advances in Neuroendocrine Neoplasms"

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".

Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 576

Special Issue Editor

Prof. Dr. Costanza Chiapponi
E-Mail Website
Guest Editor
1. Department of General, Visceral, Cancer and Transplant Surgery, University Hospital Cologne, Kerpener Str. 62, 50937 Cologne, Germany
2. Department of General and Visceral Surgery, Evangelisches Klinikum Köln Weyertal, Weyertal 76, 50937 Cologne, Germany
Interests: endocrine surgery; thyroid surgery; parathyroid surgery; adrenal surgery; neuroendocrine tumors; medical education

Special Issue Information

Dear Colleagues,

The heterogeneity of neuroendocrine neoplasms (NENs), reflected in their various levels of clinical aggressiveness and responses to therapy, has been gradually unraveled over the last several decades. Thanks to the growing number of studies and research activity, there have been several updates to our knowledge of the landscape of their diagnostic and treatment options. Novel targeted drugs, imaging tools, and radionuclides for peptide receptor radionuclide therapy (PRRT) have been introduced, leading to numerous new guidelines and guidance papers. There is a mounting awareness of the role of precision medicine, particularly in this field. The purpose of the present Special Issue is to collect original research, expert opinions, and reviews building on basic, translational, and clinical aspects of these advances and shedding light on possible future directions. 

Prof. Dr. Costanza Chiapponi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • neuroendocrine neoplasms (NENs)
  • neuroendocrine carcinomas (NECs)
  • carcinoid syndrome
  • medullary thyroid cancer (MTC)
  • gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs)
  • pheochromocytoma/paraganglioma
  • carcinoids
  • Merkel cell carcinoma (MCC)
  • small intestinal neuroendocrine neoplasms (siNENs)
  • somatostatin analogs
  • peptide receptor radionuclide therapy (PRRT)

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


21 pages, 2502 KiB  
Epidemiology of Neuroendocrine Neoplasms and Results of Their Treatment with [177Lu]Lu-DOTA-TATE or [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE—A Six-Year Experience in High-Reference Polish Neuroendocrine Neoplasm Center
Cancers 2023, 15(22), 5466; https://doi.org/10.3390/cancers15225466 - 18 Nov 2023
Viewed by 376
Neuroendocrine neoplasms (NENs) are a group of neoplasms arising from neuroendocrine cells. The worldwide incidence and prevalence of the NENs are estimated to be 6/100,000 and 35/100,000, respectively. Those numbers are increasing every decade, requiring higher and higher diagnosis and treatment costs. Radioligand [...] Read more.
Neuroendocrine neoplasms (NENs) are a group of neoplasms arising from neuroendocrine cells. The worldwide incidence and prevalence of the NENs are estimated to be 6/100,000 and 35/100,000, respectively. Those numbers are increasing every decade, requiring higher and higher diagnosis and treatment costs. Radioligand therapy (RLT) using beta-emitting radioisotopes is an efficient and relatively safe method of treatment, typically used as a second-line treatment. RLT tolerability is higher than other available pharmacotherapies (chemotherapy or tyrosine kinase inhibitors). Recent studies show an increase in overall survival among patients treated with RLT. The present study aimed to learn the epidemiology of NENs in Poland and assess the effectiveness of RLT in a high-reference center. A prospective analysis of 167 patients treated with RLT in one of Poland’s highest-reference NEN centers was performed. The analysis covered 66 months of observation (1 December 2017–30 May 2023), during which 479 RLT single administrations of radioisotope were given. The standard procedure was to give four courses of [177Lu]Lu-DOTA-TATE alone, or tandem therapy—[177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE. Grading analysis showed that most patients had non-functioning G2 NEN with a mean Ki-67 of 6.05% (SD ± 6.41). The most common primary tumor location was the pancreas. Over two-thirds of patients did undergo surgery due to primary tumors or distant metastases. The majority of patients were using lanreotide as a chronically injected somatostatin analog. Median progression-free survival (PFS) on somatostatin analogs was 21.0 (IQR = 29.0) months. Directly after the last course of RLT, disease stabilization was noted in 69.46% of patients, partial regression was noted in 20.36% of patients, complete regression was noted in 0.60% of patients, and progression was noted in 9.58% of patients. In long-term follow-up, the median observation time among patients who underwent four treatment cycles (n = 108) was 29.8 (IQR = 23.9) months. Stabilization of the disease was observed in 55.56% of the patients and progression was observed in 26.85% of the patients, while 17.59% of patients died. Median PFS was 29.3 (IQR 23.9), and the median OS was 34.0 months (IQR 16.0). The mean age of NEN diagnosis is the sixth decade of life. It takes almost three years from NEN diagnosis to the start of RLT. In long-term observation, RLT leads to disease stabilization in over half of the patients with progressive disease. No differences in PFS or OS depend on the radioisotope used for RLT. In Poland, organized coordination of NEN treatment in high-reference centers ensures the continuity of patient care. Full article
(This article belongs to the Special Issue Advances in Neuroendocrine Neoplasms)
Show Figures

Figure 1

Back to TopTop